Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for Usana Health Sciences (USNA) over the last 4 years, with Q3 2025 value amounting to $370000.0.

  • Usana Health Sciences' Asset Writedowns and Impairment fell 185.68% to $370000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 7476.5%. This contributed to the annual value of $1.9 million for FY2024, which is 2729.72% down from last year.
  • Usana Health Sciences' Asset Writedowns and Impairment amounted to $370000.0 in Q3 2025, which was down 185.68% from $834000.0 recorded in Q2 2025.
  • Over the past 5 years, Usana Health Sciences' Asset Writedowns and Impairment peaked at $2.3 million during Q2 2023, and registered a low of -$506000.0 during Q4 2023.
  • For the 3-year period, Usana Health Sciences' Asset Writedowns and Impairment averaged around $627909.1, with its median value being $423000.0 (2023).
  • Data for Usana Health Sciences' Asset Writedowns and Impairment shows a peak YoY increase of 10039.53% (in 2024) and a maximum YoY decrease of 5910.68% (in 2024) over the last 5 years.
  • Over the past 3 years, Usana Health Sciences' Asset Writedowns and Impairment (Quarter) stood at -$506000.0 in 2023, then soared by 100.4% to $2000.0 in 2024, then soared by 18400.0% to $370000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $370000.0 for Q3 2025, versus $834000.0 for Q2 2025 and $1.2 million for Q1 2025.